Dr. Hunter Land
Chief Scientific Advisor, CanaQuest Medical Corp
Dr. Hunter Land is a leading expert in cannabinoid-based therapeutics, with over two decades of research and development experience in the pharmaceutical and biotechnology industries. Currently serving as Vice President of Research & Development at Biopharmaceutical Research Company (BRC), an FDA-compliant Schedule I research facility, Dr. Land oversees the advancement of innovative cannabinoid formulations aimed at treating a broad range of medical conditions.
With a distinguished career spanning more than 25 therapeutic indications—including epilepsy, pain, multiple sclerosis, and neurodegenerative disorders—Dr. Land has spent the past 12 years at the forefront of cannabinoid science. He has developed a robust discovery pipeline of over 20 novel cannabinoids and terpenes, contributing significantly to the evolution of cannabinoid medicine.
Dr. Land’s career includes pivotal roles at industry-leading organizations. He was the first full-time R&D employee at GW Pharmaceuticals plc in the United States, where he played a central role in the clinical development of Epidiolex®—the first FDA-approved CBD medication for rare forms of epilepsy—and Sativex®, a cannabinoid-based treatment for spasticity in multiple sclerosis. He later served as Senior Scientific Director and Director of Cannabinoid Research at Canopy Growth Corporation, where he also acted as a global scientific spokesperson for the company’s R&D initiatives.
His work includes the authorship of multiple clinical protocols targeting Dravet Syndrome, Lennox-Gastaut Syndrome, MS, and chronic pain, and he is a named inventor on nine patent applications. Dr. Land has presented his research at more than 50 international conferences and has authored over 20 peer-reviewed publications. He is also a guest lecturer at the University of Wisconsin–Madison and the University of Colorado’s Skaggs School of Pharmacy and Pharmaceutical Sciences.
In addition to his leadership at BRC, Dr. Land holds several advisory and executive roles, including Chief Scientific Officer at the National Hockey League Alumni/NEEKA Brain Health Initiative, Executive Board Member at Alterola Biotech Inc., and Scientific Advisory Board Member at Nalu Bio, the Veterinary Cannabis Society, CannMed, and the Council for Federal Cannabis Regulation (CFCR). He is also a co-founder of the Cannabinoid Education Working Group, which supports scientific literacy and policy development in the cannabinoid space.
Dr. Land’s scientific leadership and industry insights have been featured in prominent publications, including Forbes and Entrepreneur. He holds a PhD and a Master of Science degree, and remains committed to advancing safe, evidence-based cannabinoid therapies through rigorous science and global collaboration.